Cascadian Therapeutics Inc. (CASC) Stock Rating Reaffirmed by Cowen and Company
Cascadian Therapeutics Inc. (NASDAQ:CASC)‘s stock had its “buy” rating restated by research analysts at Cowen and Company in a report released on Monday.
A number of other research firms also recently weighed in on CASC. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Tuesday, June 14th. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price target on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $3.20.
Cascadian Therapeutics (NASDAQ:CASC) opened at 1.34 on Monday. Cascadian Therapeutics has a one year low of $0.82 and a one year high of $3.75. The company has a 50 day moving average price of $1.33 and a 200-day moving average price of $1.18. The firm’s market capitalization is $181.32 million.
Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.14. During the same quarter in the prior year, the business earned ($0.11) earnings per share. On average, equities analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current year.
In other Cascadian Therapeutics news, insider Scott Dunseth Myers acquired 45,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The shares were acquired at an average price of $1.15 per share, with a total value of $51,750.00. Following the purchase, the insider now owns 107,500 shares of the company’s stock, valued at approximately $123,625. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 19.40% of the company’s stock.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.